Gary A. Lyons


Gary A. Lyons

Director

Mr. Lyons has served as a member of the Board of Directors of Novus Therapeutics, Inc. since May 2017.  Mr. Lyons has more than 35 years of industry experience.  Mr. Lyons is currently a member of the Board of Directors of Neurocrine Biosciences, Inc., a position he has held since 1993.  Mr. Lyons joined Neurocrine in 1993 and served as Chief Executive Officer until 2008.  Mr. Lyons also serves on the Board of Directors of Vical, Inc., Cytori Therapeutics, Inc., and is the Chairman of the Board of Directors for Rigel Pharmaceuticals, Inc. and Retrophin, Inc.  He previously served on the Board of Directors of PDL BioPharma, Inc. and Facet Biotech Corporation following Facet’s spin-off from PDL until Facet’s acquisition by Abbott Laboratories in 2010.  Mr. Lyons previously served on the Board of Directors of Poniard Pharmaceuticals, Inc., NeurogesX, Inc. and KaloBios Pharmaceuticals, Inc., each a biopharmaceutical company.  From 1983 to 1993, Mr. Lyons held a number of senior management positions at Genentech, including Vice President of Business Development and Vice President of Sales, and also served as a member of Genentech’s Executive Committee.  Mr. Lyons was responsible for international licensing, acquisitions and partnering for Genentech’s Corporate Venture Program and had operating responsibility for two subsidiaries, Genentech Canada, Inc. and Genentech Limited (Japan).  He holds a B.S. in Marine Biology from the University of New Hampshire and an M.B.A. from Northwestern University’s J.L. Kellogg Graduate School of Management.